| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2020 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CRINETICS PHARMACEUTICALS IN | 4 | Q3 2023 | 14.0% |
| CYMABAY THERAPEUTICS INC | 4 | Q3 2023 | 10.6% |
| CYTOKINETICS INC | 4 | Q3 2023 | 7.4% |
| KALVISTA PHARMACEUTICALS INC | 4 | Q3 2023 | 7.3% |
| HORIZON THERAPEUTICS PUB L | 4 | Q3 2023 | 8.1% |
| BIOGEN INC(NSM) | 4 | Q3 2023 | 7.8% |
| ASCENDIS PHARMA A/S - ADR | 4 | Q3 2023 | 6.6% |
| ITEOS THERAPEUTICS INC | 4 | Q3 2023 | 5.8% |
| MORPHIC HOLDING INC | 4 | Q3 2023 | 6.9% |
| BIOCRYST PHARMACEUTICALS INC | 4 | Q3 2023 | 7.2% |
View Saturn V Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-09 |
View Saturn V Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.